Adult Open Studies
Biology
LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Breast
SWOG-S2007
A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases
https://www.clinicaltrials.gov/ct2/show/NCT04647916
https://www.clinicaltrials.gov/ct2/show/NCT04647916
CNS
Glioma
INV INT-Differentiating Glioma (AXUMIN)- 5180227
Differentiating brain tumor recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://www.clinicaltrials.gov/ct2/show/NCT03925675
https://www.clinicaltrials.gov/ct2/show/NCT03925675
Glioblastoma
SWOG-NRG-BN007
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
https://www.clinicaltrials.gov/ct2/show/NCT04396860
https://www.clinicaltrials.gov/ct2/show/NCT04396860
COVID-19
Statera BioPharma-ST205-101-002
Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients with Mild COVID 19 Who Are at High Risk of Disease Progression
https://clinicaltrials.gov/ct2/show/NCT04708327
https://clinicaltrials.gov/ct2/show/NCT04708327
SWOG-NRG-BN007
The COVID-19 and Cancer Consortium (CCC19) Registry
https://clinicaltrials.gov/ct2/show/NCT04354701
https://clinicaltrials.gov/ct2/show/NCT04354701
Germ Cell
SWOG-S1823
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT04435756
GI
Esophageal
Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
https://clinicaltrials.gov/ct2/show/NCT01684904
Pancreas
INV INT-Pancreatic - 5170277
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma
https://www.clinicaltrials.gov/ct2/show/NCT03492671
https://www.clinicaltrials.gov/ct2/show/NCT03492671
Liver
NeuWave NEU-2017-04
A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://www.clinicaltrials.gov/ct2/show/NCT04107766
https://www.clinicaltrials.gov/ct2/show/NCT04107766
Liver
Neuwave-NEU-2017-03
A Multicenter Study to Evaluate NEUWAVE Microwave Ablation System Using Ablation Confirmation in Patients with A Soft-Tissue Liver Lesion
https://www.clinicaltrials.gov/ct2/show/NCT03753789
https://www.clinicaltrials.gov/ct2/show/NCT03753789
Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371
https://clinicaltrials.gov/ct2/show/NCT01697371
Colon
Penn State-Colon Registry - 5180134
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Colorectal
SWOG-S0820
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with E
https://www.clinicaltrials.gov/ct2/show/NCT1349881
https://www.clinicaltrials.gov/ct2/show/NCT1349881
GU
Prostate
COMPPARE
Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03561220
https://clinicaltrials.gov/ct2/show/NCT03561220
Bladder
SWOG-S1600
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMmune)
https://www.clinicaltrials.gov/ct2/show/NCT03757949
https://www.clinicaltrials.gov/ct2/show/NCT03757949
Bladder
UROGEN-BL011
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
https://www.clinicaltrials.gov/ct2/show/NCT05243550
https://www.clinicaltrials.gov/ct2/show/NCT05243550
Urothelial
QED-QGBJ398-302
The Proof 302 study of infigratinib in adjuvant urothelial carcinoma is launching soon and patients can be identified NOW
https://clinicaltrials.gov/ct2/show/NCT04197986
https://clinicaltrials.gov/ct2/show/NCT04197986
GYN
Multiple
INV INT Paclitaxel - 5180198
Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426
https://clinicaltrials.gov/ct2/show/NCT03598426
Ovarian
INV INT-Ovarian HIPEC-5150302
Investigator Initiated HIPEC Ovarian: Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098
https://clinicaltrials.gov/ct2/show/NCT02672098
Ovarian/ Peritoneum
SWOG-NRG-GY019
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://www.clinicaltrials.gov/ct2/show/NCT04095364
https://www.clinicaltrials.gov/ct2/show/NCT04095364
Lung
ALLIANCE-A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738
https://clinicaltrials.gov/ct2/show/NCT02194738
NSCLC
ECOG-ACRIN-E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992
https://clinicaltrials.gov/ct2/show/NCT02201992
NSCLC
ALLIANCE-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://www.clinicaltrials.gov/ct2/show/NCT04267848
https://www.clinicaltrials.gov/ct2/show/NCT04267848
NSCLC
SWOG-S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
https://clinicaltrials.gov/ct2/show/NCT04214262
https://clinicaltrials.gov/ct2/show/NCT04214262
NSCLC
SWOG-RTOG-1308
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
https://clinicaltrials.gov/ct2/show/NCT01993810
https://clinicaltrials.gov/ct2/show/NCT01993810
NSCLC
SWOG-LUNGMAP
A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
https://www.clinicaltrials.gov/ct2/show/NCT02154490
https://www.clinicaltrials.gov/ct2/show/NCT02154490
SCLC
SWOG-S1929
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04334941
https://clinicaltrials.gov/ct2/show/NCT04334941
LS-SCLC
Merck-MK-7339-013-02
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04624204
https://clinicaltrials.gov/ct2/show/NCT04624204
NSCLC
SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
https://clinicaltrials.gov/ct2/show/NCT04267848
Melanoma
Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
https://clinicaltrials.gov/ct2/show/NCT02355587
Multiple
SWOG-S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013
https://clinicaltrials.gov/ct2/show/NCT02834013
UOP-Ostomy Telehealth
Ostomy Telehealth Self-Management Training for Cancer Survivors
https://www.clinicaltrials.gov/ct2/show/NCT03913715
https://www.clinicaltrials.gov/ct2/show/NCT03913715
Registry
Radiation Medicine
Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941
https://clinicaltrials.gov/ct2/show/NCT02436941
Penn State-Colon Registry
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Soft Tissue Sarcoma
Radiation Medicine
A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831
https://clinicaltrials.gov/ct2/show/NCT01819831
Solid Tumors
Apollomics-APL-101-01
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03175224
https://clinicaltrials.gov/ct2/show/NCT03175224
Amgen-20190135-A
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (proposed generic name for AMG 510) in Combination With Trametinib and in Combination With Trametinib and Panitumumab in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol A)
https://clinicaltrials.gov/ct2/show/NCT03600883
https://clinicaltrials.gov/ct2/show/NCT03600883
Amgen-20190135-C
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
(CodeBreak 101 Subprotocol C)
https://clinicaltrials.gov/ct2/show/NCT04185883
(CodeBreak 101 Subprotocol C)
https://clinicaltrials.gov/ct2/show/NCT04185883
Amgen-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
https://clinicaltrials.gov/ct2/show/NCT04185883
https://clinicaltrials.gov/ct2/show/NCT04185883
Transplant
PTLD
ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
https://clinicaltrials.gov/ct2/show/NCT03394365
Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050